share_log

BriaCell Highlights Data For Antibody-Drug Conjugate Resistant And Central Nervous System Metastatic Breast Cancer At AACR 2024

Benzinga ·  Apr 9 08:49
  • PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT pivotal Phase 3 formulation is twice that of controls in similar studies
  • PFS results reinforced by larger number of prior treatments in Bria-IMT population than in comparable studies
  • Bria-IMT PFS compares favorably to their most recent treatment PFS in 48% of patients
  • Clinical benefit rate of 56% in evaluable patients
  • 71% intracranial objective response rate (iORR) in heavily pretreated patients
  • Findings support clinical efficacy of Bria-IMT and highlight its significant potential in managing CNS metastatic disease in advanced breast cancer
    • Additional preclinical anti-cancer data of Bria-OTS+ and Bria-PROS+ will be presented tomorrow 9:00 AM - 12:30 PM PST; Abstract Presentation Number: 6753
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment